Dimpi Nitin Desai, MD
Endocrinology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
16 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Desai’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A179196 · Current
Licensed to practise in California · since 2022 · expires 2028-06-30 · Maharashtra University of Health Services, Topiwala National Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas S3151Physician License · since 2019 · expires 2023-08-31Cancelled By RequestNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$71,090
Medicare paid this office $71,090 for 247 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 73 | $28,273 | $70 |
| Return visit (30+ min) | 109 | $22,420 | $120 |
| Return visit (30+ min) | 51 | $5,697 | $76 |
| Long return visit (40+ min) | 18 | $3,990 | $166 |
| New patient visit (45+ min) | 19 | $2,845 | $150 |
See all 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 73 | $28,273 | $70 |
| Return visit (30+ min) | 109 | $22,420 | $120 |
| Return visit (30+ min) | 51 | $5,697 | $76 |
| Long return visit (40+ min) | 18 | $3,990 | $166 |
| New patient visit (45+ min) | 19 | $2,845 | $150 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $2,798 | $112 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 31 | $1,510 | $31 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 43 | $869 | $15 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 19 | $299 | $15 |
Who their Medicare patients are
247 Original Medicare patients in 2024. Average age 70 · Under 65 18% · 85 and older 6% · Women 56% · Also on Medicaid 44% · Health risk score 2.85. Sicker patients than 9 in 10 peers; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 75% · Diabetes 75% · Chronic kidney disease 47% · Coronary heart disease 36% · Heart failure 33% · Atrial fibrillation 31% · Cancer 29% · Depression 26% · COPD 20% · Dementia 17% · Stroke 12%.
The office billed $340,788, Medicare allowed $92,078 and paid $71,090; for 883 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 247 | 883 | 70 | 2.85 | $340,788 | $71,090 |
| 2023 | 167 | 618 | 71 | 2.96 | $228,582 | $49,323 |
| 2022 | 190 | 429 | 68 | 2.16 | $130,941 | $30,339 |
| 2021 | 138 | 284 | 64 | 2.42 | $80,640 | $21,473 |
| 2020 | 100 | 177 | 67 | 1.72 | $45,474 | $12,915 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $20,058 | $72 |
| Return visit (30+ min) | 82 | $15,508 | $86 |
| New patient visit (45+ min) | 57 | $6,090 | $107 |
| Long return visit (40+ min) | 23 | $3,431 | $132 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 19 | $1,114 | $32 |
2022: 8 services
| Return visit (30+ min) | 103 | $13,382 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $5,030 | $64 |
| New patient visit (45+ min) | 19 | $2,179 | $115 |
| New patient visit (45+ min) | 22 | $1,897 | $86 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,856 | $109 |
| Return visit (30+ min) | 12 | $1,071 | $89 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $976 | $89 |
| Hemoglobin a1c level | 53 | $607 | $9 |
2021: 7 services
| Return visit (30+ min) | 75 | $9,511 | $88 |
| Short return visit (20+ min) | 30 | $2,949 | $72 |
| New patient visit (45+ min) | 15 | $1,751 | $117 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,670 | $152 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | $1,446 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,226 | $111 |
| Hemoglobin a1c level | 37 | $398 | $10 |
2020: 5 services
| Return visit (30+ min) | 49 | $5,043 | $90 |
| New patient visit (45+ min) | 24 | $3,022 | $126 |
| Short return visit (20+ min) | 30 | $1,972 | $62 |
| New patient visit (30+ min) | 17 | $1,412 | $83 |
| Hemoglobin a1c level | 26 | $282 | $10 |
Medicaid work
$22,943 in 2024
Medicaid paid $22,943 for 381 billed services this clinician did in 2024, up to 28 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 238 | $17,837 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 143 | $5,106 |
| 2024 | 381 | 2 | 28 | $22,943 |
| 2023 | 293 | 3 | 32 | $14,938 |
| 2022 | 253 | 3 | 28 | $12,034 |
| 2021 | 15 | 1 | 14 | $743 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 240 | $11,838 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 12 | $1,560 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 41 | $1,540 |
2022
| Return visit (30+ min) | 165 | $10,693 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 58 | $1,153 |
| Hemoglobin A1C level | 30 | $188 |
2021
| Return visit (30+ min) | 15 | $743 |
Drugs they prescribed that Part D paid
$351,782
Pharmacies billed $351,782 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 983) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
346 generic and 512 brand-name prescriptions · $351,782 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 94 | $92,950 | $989 |
| Mounjaro | 72 | $69,959 | $972 |
| Trulicity | 35 | $45,288 | $1,294 |
| Jardiance | 31 | $29,992 | $967 |
| Wegovy | 19 | $26,467 | $1,393 |
See all 24 drugs
| Ozempic | 94 | $92,950 | $989 |
| Mounjaro | 72 | $69,959 | $972 |
| Trulicity | 35 | $45,288 | $1,294 |
| Jardiance | 31 | $29,992 | $967 |
| Wegovy | 19 | $26,467 | $1,393 |
| Januvia | 17 | $14,292 | $841 |
| Basaglar Kwikpen U-100 | 27 | $8,137 | $301 |
| Insulin Lispro Kwikpen U-100 | 23 | $4,243 | $184 |
| Ultra-Fine Mini Pen Needle | 45 | $3,132 | $70 |
| Lantus Solostar | 25 | $2,546 | $102 |
| Novolog Mix 70-30 Flexpen | 15 | $2,498 | $167 |
| Humalog Kwikpen U-100 | 14 | $2,393 | $171 |
| Insulin Aspart Flexpen | 13 | $2,365 | $182 |
| Ultra-Fine Nano Pen Needle | 29 | $2,030 | $70 |
| Hydrocortisone | 54 | $1,993 | $37 |
| Nano 2nd Gen Pen Needle | 15 | $1,348 | $90 |
| Comfort Ez Pen Needle | 13 | $1,249 | $96 |
| Levothyroxine | 92 | $897 | $10 |
| Synthroid | 11 | $843 | $77 |
| Metformin Hcl Er | 68 | $736 | $11 |
| Metformin | 49 | $364 | $7 |
| Glipizide | 49 | $323 | $7 |
| Atorvastatin | 14 | $182 | $13 |
| Methimazole | 16 | $94 | $6 |
Year by year
| 2024 | 983 | 138 | 0% (0) | 52% | $351,782 |
| 2023 | 967 | 206 | 0% (0) | 45% | $342,506 |
| 2022 | 1,491 | 215 | 0% (0) | 53% | $661,410 |
| 2021 | 909 | 140 | 0% (0) | 59% | $404,652 |
| 2020 | 289 | 103 | 0% (0) | 56% | $101,754 |
| 2019 | 235 | 57 | 0% (0) | 57% | $140,436 |
| 2018 | 354 | 72 | 0% (0) | None | $83,311 |
| 2017 | 385 | 54 | 0% (0) | None | $31,972 |
| 2016 | 369 | 34 | 0% (0) | None | $15,507 |
| 2015 | 35 | None | 0% (0) | 34% | $1,921 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 22 drugs
| Trulicity | 51 | $66,607 | $1,306 |
| Ozempic | 60 | $61,755 | $1,029 |
| Lantus Solostar | 30 | $22,827 | $761 |
| Humalog Kwikpen U-100 | 24 | $22,735 | $947 |
| Jardiance | 12 | $15,098 | $1,258 |
| Januvia | 17 | $12,302 | $724 |
| Mounjaro | 11 | $12,065 | $1,097 |
| Novolog Flexpen | 18 | $10,579 | $588 |
| Novolog | 18 | $7,881 | $438 |
| Basaglar Kwikpen U-100 | 23 | $7,770 | $338 |
| Novolog Mix 70-30 Flexpen | 11 | $7,325 | $666 |
| Nano 2nd Gen Pen Needle | 36 | $3,886 | $108 |
| Ultra-Fine Mini Pen Needle | 42 | $3,439 | $82 |
| Levothyroxine | 117 | $1,652 | $14 |
| Ultra-Fine Nano Pen Needle | 14 | $1,512 | $108 |
| Hydrocortisone | 51 | $1,345 | $26 |
| Metformin Hcl Er | 60 | $1,310 | $22 |
| Glipizide | 55 | $556 | $10 |
| Metformin | 50 | $417 | $8 |
| Glipizide Er | 11 | $368 | $33 |
| Methimazole | 24 | $269 | $11 |
| Atorvastatin | 19 | $244 | $13 |
2022: 30 drugs
| Ozempic | 146 | $172,529 | $1,182 |
| Trulicity | 70 | $92,478 | $1,321 |
| Jardiance | 67 | $61,776 | $922 |
| Lantus Solostar | 82 | $51,313 | $626 |
| Humalog Kwikpen U-100 | 40 | $38,023 | $951 |
| Novolog Flexpen | 41 | $28,383 | $692 |
| Levemir Flextouch | 40 | $28,016 | $700 |
| Tradjenta | 25 | $21,493 | $860 |
| Novolog | 19 | $21,408 | $1,127 |
| Januvia | 19 | $17,144 | $902 |
| Tresiba Flextouch U-100 | 21 | $12,766 | $608 |
| Humalog | 12 | $10,380 | $865 |
| Basaglar Kwikpen U-100 | 26 | $10,204 | $392 |
| Farxiga | 16 | $8,682 | $543 |
| Nano 2nd Gen Pen Needle | 50 | $5,011 | $100 |
| Insulin Lispro Kwikpen U-100 | 12 | $2,195 | $183 |
| Levothyroxine | 127 | $2,161 | $17 |
| Synthroid | 30 | $2,044 | $68 |
| Ultra-Fine Mini Pen Needle | 17 | $1,862 | $110 |
| Metformin Hcl Er | 66 | $922 | $14 |
| Ultra-Fine Micro Pen Needle | 12 | $817 | $68 |
| Atorvastatin | 86 | $741 | $9 |
| Hydrocortisone | 14 | $522 | $37 |
| Glipizide | 66 | $448 | $7 |
| Glipizide Er | 29 | $435 | $15 |
| Metformin | 48 | $423 | $9 |
| Methimazole | 15 | $163 | $11 |
| Rosuvastatin | 13 | $148 | $11 |
| Lisinopril | 25 | $119 | $5 |
| Hydrochlorothiazide | 11 | $36 | $3 |
2021: 23 drugs
| Ozempic | 64 | $74,654 | $1,166 |
| Trulicity | 52 | $59,184 | $1,138 |
| Novolog Flexpen | 45 | $34,468 | $766 |
| Jardiance | 45 | $30,191 | $671 |
| Lantus Solostar | 48 | $24,868 | $518 |
| Levemir Flextouch | 31 | $24,511 | $791 |
| Tradjenta | 23 | $19,779 | $860 |
| Humalog Kwikpen U-100 | 23 | $18,866 | $820 |
| Januvia | 22 | $13,031 | $592 |
| Victoza 2-Pak | 12 | $8,590 | $716 |
| Basaglar Kwikpen U-100 | 20 | $8,274 | $414 |
| Tresiba Flextouch U-100 | 14 | $7,277 | $520 |
| Nano 2nd Gen Pen Needle | 30 | $2,249 | $75 |
| Levothyroxine | 87 | $1,572 | $18 |
| Synthroid | 15 | $1,137 | $76 |
| Hydrocortisone | 17 | $923 | $54 |
| Atorvastatin | 45 | $477 | $11 |
| Calcitriol | 19 | $374 | $20 |
| Metformin Hcl Er | 30 | $356 | $12 |
| Glipizide | 29 | $266 | $9 |
| Metformin | 18 | $156 | $9 |
| Alendronate | 11 | $101 | $9 |
| Lisinopril | 14 | $39 | $3 |
2020: 7 drugs
| Ozempic | 14 | $18,808 | $1,343 |
| Lantus Solostar | 15 | $4,704 | $314 |
| Synthroid | 16 | $1,190 | $74 |
| Levothyroxine | 28 | $424 | $15 |
| Hydrocortisone | 13 | $383 | $29 |
| Metformin Hcl Er | 19 | $296 | $16 |
| Metformin | 13 | $74 | $6 |
2019: 4 drugs
| Synthroid | 21 | $2,238 | $107 |
| Levothyroxine | 51 | $1,014 | $20 |
| Hydrocortisone | 22 | $892 | $41 |
| Metformin Hcl Er | 17 | $350 | $21 |
2018: 14 drugs
| Forteo | 12 | $46,216 | $3,851 |
| Symbicort | 13 | $4,380 | $337 |
| Hydrocortisone | 11 | $631 | $57 |
| Ventolin Hfa | 11 | $598 | $54 |
| Levothyroxine | 12 | $413 | $34 |
| Nifedipine Er | 12 | $347 | $29 |
| Metformin | 34 | $177 | $5 |
| Amlodipine Besylate | 24 | $138 | $6 |
| Gabapentin | 15 | $132 | $9 |
| Lisinopril | 15 | $90 | $6 |
| Atorvastatin | 11 | $83 | $8 |
| Naproxen | 12 | $71 | $6 |
| Simvastatin | 13 | $36 | $3 |
| Losartan | 12 | $35 | $3 |
2017: 10 drugs
| Ventolin Hfa | 11 | $582 | $53 |
| Nifedipine Er | 24 | $505 | $21 |
| Fluticasone Propionate | 17 | $242 | $14 |
| Losartan | 23 | $164 | $7 |
| Gabapentin | 11 | $112 | $10 |
| Ranitidine | 16 | $60 | $4 |
| Amlodipine Besylate | 16 | $52 | $3 |
| Metformin | 13 | $46 | $4 |
| Simvastatin | 19 | $36 | $2 |
| Hydrochlorothiazide | 21 | $29 | $1 |
2016: 10 drugs
| Ventolin Hfa | 12 | $615 | $51 |
| Divalproex | 12 | $507 | $42 |
| Nifedipine Er | 14 | $391 | $28 |
| Levothyroxine | 15 | $234 | $16 |
| Montelukast | 22 | $207 | $9 |
| Losartan | 23 | $85 | $4 |
| Metformin | 17 | $39 | $2 |
| Prednisone | 12 | $26 | $2 |
| Simvastatin | 16 | $23 | $1 |
| Amlodipine Besylate | 11 | $14 | $1 |
Money from drug and device companies
$236 in 2025
| 2025 | 2 | 2 | None | $236 |
| 2024 | 1 | 1 | None | $121 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Dexcom | Dexcom G6 Transmitter | $153 | 1 payment
|
| Novo Nordisk | Wegovy | $82 | 1 payment
|
See all 2 published payments
| Novo Nordisk | Meals · 2025-11-06 | Wegovy | $82 |
| Dexcom | Meals · 2025-10-23 | Dexcom G6 Transmitter | $153 |
See earlier years (2024)
2024: $121
| Abbott Laboratories | Freestyle Libre 3 | $121 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1780060699
- Licence
- CA A179196, TX S3151California A179196: Current · expires 2028-06-30Texas S3151: Cancelled By Request
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2015-08-03
- NPI last updated
- 2024-04-28
- NPI record certified
- 2024-04-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1400 Pelham Parkway S,, New York, NY, 10461